Discover investment opportunities in Top Pharma Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top Pharma Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top Pharma Stocks using our Smart AI Filter.
10 stocks found for "Top Pharma Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.60 | ±27.2% | 15.6 | 3.47% | |||
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.35 | ±28.9% | 6.7 | 5.29% | |||
0.45 | ±25.0% | 14.4 | 3.19% | |||
0.59 | ±31.6% | 34.5 | 0.77% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.32 | ±24.8% | 8.7 | 6.75% | |||
0.33 | ±27.9% | 8.6 | 4.00% | |||
0.37 | ±19.7% | 14.7 | 3.18% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read morePresident Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Read moreQ: How does Pfizer (PFE) balance between growth and dividend income potential?
A: Pfizer (PFE) provides investors with a solid dividend yield. Historically, PFE balances dividend income with growth via its innovative drug pipeline and strategic acquisitions. Future revenue growth may depend on drug approvals and health policies. Investors might find its blend of growth potential and robust dividends appealing.
Q: What competitive advantages does Johnson & Johnson (JNJ) hold in the current market landscape?
A: Johnson & Johnson (JNJ) gains competitive advantages from its diversified product portfolio in pharmaceuticals, medical devices, and consumer health. This diversity stabilizes revenues across economic cycles, allowing sustained investment in R&D and consistent dividend payouts, appealing to both growth and income-focused investors.
Q: In terms of sector-specific risks, what should investors consider with Merck (MRK)?
A: Merck (MRK) may face risks related to drug patent expirations, regulatory changes, and healthcare pricing pressures. Its exposure to these risks is mitigated by a strong R&D pipeline and a focus on oncology and vaccines, which are significant growth areas.
Q: What opportunities do Eli Lilly (LLY) present for growth-oriented investors?
A: Eli Lilly (LLY) offers growth opportunities through its robust portfolio in diabetes and cancer treatments. Recent innovations and successful drug trials suggest potential revenue increases. The company's investment in biotech advancements may also provide long-term growth prospects.
Q: How might Bristol-Myers Squibb (BMY) appeal to value investors?
A: For value investors, Bristol-Myers Squibb (BMY) may appeal due to its strong cash flow, a focus on cost management, and strategic acquisitions. Its relatively low P/E ratio compared to peers can be an attractive entry point, particularly if its drug pipeline continues to show promise.
Q: What factors contribute to AbbVie's (ABBV) dividend sustainability?
A: AbbVie (ABBV) has a strong history of dividend payouts supported by consistent cash flow, primarily from its flagship product, Humira. Diversifying into new therapeutic areas and successful integration of acquisitions contribute to future dividend sustainability but diversification beyond Humira remains crucial.